News stories about Sientra (NASDAQ:SIEN) have trended somewhat positive on Friday, Accern reports. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sientra earned a news sentiment score of 0.05 on Accern’s scale. Accern also assigned news headlines about the medical instruments supplier an impact score of 47.4095874408973 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Several brokerages have recently weighed in on SIEN. Canaccord Genuity reiterated a “buy” rating and issued a $14.00 price objective on shares of Sientra in a research note on Sunday, October 8th. Stifel Nicolaus reiterated a “hold” rating and issued a $14.00 price objective (up previously from $11.00) on shares of Sientra in a research note on Wednesday, September 27th. William Blair upgraded shares of Sientra from a “market perform” rating to an “outperform” rating in a research note on Wednesday, September 13th. Lake Street Capital reiterated a “buy” rating and issued a $15.00 price objective (up previously from $11.00) on shares of Sientra in a research note on Tuesday, August 8th. Finally, Zacks Investment Research cut shares of Sientra from a “hold” rating to a “sell” rating in a research note on Tuesday, August 15th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $13.75.

Sientra (NASDAQ:SIEN) opened at $14.04 on Friday. Sientra has a one year low of $7.20 and a one year high of $16.68. The company has a current ratio of 2.87, a quick ratio of 1.92 and a debt-to-equity ratio of 0.57.

Sientra (NASDAQ:SIEN) last released its earnings results on Tuesday, November 7th. The medical instruments supplier reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.06). Sientra had a negative return on equity of 68.82% and a negative net margin of 169.77%. The firm had revenue of $9.80 million for the quarter, compared to the consensus estimate of $10.54 million. During the same quarter in the previous year, the business posted ($0.55) EPS. Sientra’s revenue was up 50.8% on a year-over-year basis. equities analysts forecast that Sientra will post -3.14 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at

Sientra Company Profile

Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.

Insider Buying and Selling by Quarter for Sientra (NASDAQ:SIEN)

Receive News & Ratings for Sientra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.